Oramed Pharmaceuticals Inc.
Company Snapshot: Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (POD™) technology is based on over 30 years of research by top scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The Company completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).
- Nov 24 2020 Oramed Initiates Phase 3 Trial of Oral Insulin
- Nov 12 2020 Nobel Laureate, Oramed SAB member Prof. Avram Hershko and Oramed CSO Dr. Miriam Kidron to be Featured on Biotalknology Webinar "Oral Delivery of Therapeutic Proteins - Oramed Story" on November 18, 2020
- Nov 10 2020 Oramed to Present at H.C. Wainwright 6th Annual Israel Conference
- Oct 28 2020 Oramed to Present Phase 2b Oral Insulin Data at American Association of Pharmaceutical Scientists 2020 PharmSci 360 Conference
- Oct 27 2020 Oramed CEO Nadav Kidron & Premas Biotech to Host Webinar "The Journey of Oral Insulin: Oramed Story" on Wednesday October 28, 2020